The pandemic shined a light on the biotech and pharmaceutical sector, with their prices for shares climbed to new heights in the aftermath.
The major pharmaceutical companies have performed well until 2022 despite the fact that other sectors struggle in confront of the crisis in living costs and the rise in inflation.
A broad exposure to the industry allows investors to profit from the growing demand over time for healthcare services.
Pharma has experienced significant changes in the last few years.
As the Covid vaccines made news the years of research getting fruitful for major players such as AstraZeneca along with GlaxoSmithKline.
With a recession in the near future, can pharmaceutical companies be in a position to maintain their growth? It could be the right opportunity to make an investment in biotech companies that have seen their stock prices plummet?
Its Covid vaccine has increased AstraZeneca’s global visibility significantly. in February, it announced an all-time high in revenue comprising $1.8billion of the Covid vaccine as well as the sales of the acquisition of $39 billion of Alexion. The company also raised its dividend by the highest amount in 10 years.
AstraZeneca is currently the second-largest FTSE 100 company by market size after it doubled its share price over five years. It is also a favorite among income funds like Artemis and the Columbia Threadneedle UK Equity Income Fund.
Big Pharma as represented by FTSE 100’s constituents AstraZeneca as well as GlaxoSmithKline have done well during the overall market downturn this year. The shares of both companies are up 28 percent and 8 percent, each, for the year-to-date according to Garry White, Charles Stanley’s chief investment analyst.
Sales of the Covid-19 vaccine are slowing down, however the ease of pandemic restrictions have helped boost sales of other vaccines. The sales of cancer medications have been increasing and the main players have plenty of pipelines for promising new products that are in the process of being developed.’
GSK has also done very well. In the initial quarter, sales grew by 32 percent and operating profits grew by 65 per cent.
However, it faces an uncertain road ahead following the disposal of Haleon’s consumer division Haleon that is been listed this week at the London Stock Exchange.
The demerger is likely to alter the structure of GSK in the process of becoming an independent pharma group. Its business in consumer healthcare was generally predictable, with a steady earnings, and its shares already plummeted since Haleon’s debut.
Although Haleon’s trading on its opening day was at the lower than expected For investors seeking the stability of a steady income, it may prove to be a worthwhile investment.
Fundamentally, this is a very attractive industry and business to take exposure to due to its defense-oriented characteristics in an era when volatility is disrupting markets according to Chris Beckett, head of equity research at Quilter Cheviot.
The company itself is a leader in its brand names and market positions in the fields of oral health and digestive health, pain relief and vitamins, as well as respiratory health, and there’s no reason to believe that they can’t be sustained.’
What is the best way to ensure that pharmaceuticals are recession-proof?
The general demand for stocks has been resilient, despite the economic recession, since they’re considered to be safer and have a higher level of security.
Ailsa Craig, joint chief investment manager for International Biotechnology Trust says: In times of downturn, food and healthcare are often viewed as top priorities by people, and the need for medical care is not diminished. Indeed, the percentage of over 65-year older who are most likely to require medical attention is expected to double in the coming years.
Therefore, even though insurance coverage could be reduced which could result in some pressure on prices, especially for non-essential treatments, the overall market sales in the pharmaceutical sector, specifically of medicines that treat critical ailments, are not likely to be significantly affected by a decline of economic activity.’
Conglomerates in the field of healthcare have traditionally been an amalgamation of diverse companies that include pharmaceuticals, consumer health and animal health, while some may even have medical device companies.
There is a consensus that a large group of people will provide you with an even more secure portfolio. Health care is considered to be defensive… pharmaceuticals can appear defensive, but you have to purchase more products since they lose exclusivity. There are more troughs and peaks, according to Andrew Duncan, senior equity analyst at Killick.
How do investors decide which are the most suitable for them to put their money into?
Investors should seek out a company that has a good reputation for Research and Development (R&D) and a solid pipeline, and a track record of providing that pipeline Duncan says. Duncan. You must have a lot of eggs in your basket.
We look at the general direction of the travel… We try at investing in businesses that contribute to the R&D world. Tools and life sciences sector… there’s need for services, but we’re not relying on the performance of a particular prototype or experiment.’
Companies set to profit from this trend include the US-listed Thermofisher that specializes in scientific research and recently bought the business of clinical trials.
Is it the right moment to invest in biotech stocks that are volatile?
Biotech companies, situated at the crossroads of tech and pharma, have also been the recipients of the vaccination bounce.
After soaring in 2020, the shares of biotech companies have plummeted in the wake of the shift away from stocks that are growing. It is worth noting that the Nasdaq Biotechnology Index has seen volatility over the past three years, with its highest in 2021 before an extended decline.
This overshooting and adjustment in performance is not unusual for biotech companies, however the overall trend has been positive, with performance that was higher than that of the UK FTSE 100 over the last three years Craig adds. Craig.
International Biotechnology Trust is unusual among investment trusts that focus on growth that pay a large dividend. The current yield of 5.01 percent.
The trust is home to a wide variety of companies, with the majority of that have a drug approved that is already available for sale. They include Horizon Therapeutics, Incite and Neurocrine.
Although biotech is an interesting investment opportunity for investors, it’s highly risky. Investors who buy individual stocks could be exposed to extreme risk.
White says: “The current issue for businesses operating on the forefront in biotech lies with the fact that just like the research and development that is carried out in the more conventional tech industries, these companies require a significant amount of capital to begin in their R&D.
The revenues they earn from their products, despite the fact that they might be significant but are not likely to be realized in the near future. It’s all about “jam tomorrow’.
“This type of business is dependent on borrowing. Higher borrowing costs now means lower profits in the long term.
The quantity of their interest be required to pay now has an immediate impact on the value of these companies in models used by City analysts. With interest rates rising the forecasts for future earnings and price expectations are reduced.’
Biotech’s hottest product Oxford Nanopore has certainly suffered since its debut on the market in the year 2000. It’s down 32 percent since the date of its debut and has dropped 56 per cent from the time of its listing to date.
In March, the company reported that its the annual loss jumped over PS100million due to the costs linked the IPO and share-based payment. The company also suffered following the expiration of its contract in partnership with the Department of Health and Social Care which provided rapid Covid tests.
White continues: “The future for healthcare is certain to be positive, with promising developments in areas such as the use of mRNA-based vaccinations, gene therapy and monoclonal antibodies.
The general mood towards the biotech industry is in a cyclical fashion and the pressure to structurally improve the more raucous section is still significant.
Inflation, rising interest rates and geopolitical instability add to the negative sentiment around these investments due to the time frame they must earn a profit which means they are long-term and risky investments.
Negative influences that could affect the outlook for the sector remain in place for a while. It is probable to be the case that Big Pharma, with its various product portfolios and numerous revenue streams, will continue to be the most preferred method for investors to invest for a while. At present, safety is the most important factor.’